Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.
KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
The user is experiencing hair loss and is considering increasing their dutasteride dosage or trying RU58841, but is concerned about the effectiveness and side effects. Other users suggest sticking with dutasteride 0.5 mg daily and adding oral minoxidil for better results.
There is no imminent cure for hair loss, but treatments like Minoxidil, Finasteride, and new drugs such as KX-826, GT-20029, and PP405 are being explored. Current solutions focus on slowing hair loss and stimulating growth, with hopes for better options in the future.
A person had three hair transplant surgeries using 7,600 grafts from scalp, beard, and chest, along with finasteride and minoxidil. Reactions are mixed, with suggestions for alternatives like hair systems or scalp micropigmentation.
Hair loss treatments have not advanced since 2018, with finasteride, minoxidil, and RU58841 still being the main options. A permanent cure is unlikely due to the profitability of ongoing treatments.
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
Dutasteride tablets from India are significantly cheaper than those from pharmacies, but there are concerns about authenticity and customs issues. The user is also using oral minoxidil, finasteride, and RU58841 for hair loss treatment.
The user shared their 5-year progress using finasteride and topical minoxidil for hair growth, noting initial success but recent thinning and side effects. They plan to switch to dutasteride and oral minoxidil, addressing low iron levels and monitoring potential side effects.
The user has been using finasteride for six years and minoxidil for three years with no noticeable hair regrowth. Suggestions include switching to dutasteride, considering a hair transplant, and trying microneedling.
Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.
Dutasteride is more effective than finasteride for hair loss, with optimal dosing at 0.5mg once or twice a week to minimize side effects. Topical application may further reduce side effects while effectively lowering scalp DHT.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
The user achieved significant hair regrowth using 0.5mg oral Dutasteride, 2.5mg oral Minoxidil, topical Minoxidil twice daily, Ketoconazole shampoo twice a week, and weekly dermastamping with no side effects. Results were noticeable after 2-3 months, with the best results at 9 months.
Finasteride is generally seen as more successful for hair loss than Dutasteride, with fewer negative experiences reported. Dutasteride is considered more effective but often leads to more complaints, possibly due to higher expectations or improper use.
The user looks good bald and could enhance their appearance by gaining muscle and growing facial hair. Some suggest trying minoxidil and finasteride, while others recommend embracing baldness and focusing on confidence.
Finasteride may help users look younger by suppressing DHT, affecting skin and hair. Users also emphasize skincare, sunscreen, and lifestyle for maintaining a youthful appearance.
Finasteride can help maintain hair and slow hair loss, but its effectiveness varies by individual. Some may switch to dutasteride or add minoxidil for better results, though side effects are a concern.
Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.
A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.
PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
Baldness is not an evolutionary disadvantage because it occurs after reproductive age. Treatments like Minoxidil and Finasteride are used for androgenetic alopecia but don't address the root cause.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
The user experienced successful hair regrowth with Finasteride and Minoxidil but developed erectile dysfunction and abdominal pain, possibly due to medication or lifestyle changes. They plan to consult a urologist and consider adjusting medication or trying supplements like zinc, DIM, or boron.